Endologix to Report Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014

IRVINE, Calif., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2013 financial results, which will take place on Thursday, February 27, 2014 after the close of the market.

Endologix will hold a conference call on Thursday, February 27, 2014 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and to provide updates on Endologix's operations and product pipeline. The dial-in numbers are (877) 407-0789 for domestic callers and (201) 689-8562 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.endologix.com.

After the live webcast, a transcript of the call will remain available online from the investor relations page of Endologix's website, www.endologix.com, through March 27, 2014. In addition, a telephonic replay of the call will be available until March 6, 2014. The replay dial-in numbers are (877) 870-5176 for domestic callers and (858) 384-5517 for international callers. Please use the replay pin number 13575324.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.

CONTACT: COMPANY CONTACT:

Endologix, Inc.
John McDermott, CEO
Shelley Thunen, CFO
(949) 595-7200
www.endologix.com

INVESTOR CONTACTS:

The Ruth Group
Nick Laudico (646) 536-7030
Zack Kubow (646) 536-7020

Source: Endologix

News Provided by Acquire Media